Phase III
Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia
Alex Trebek, 78, host of TV game show “Jeopardy” announced yesterday that he had been diagnosed with stage 4 pancreatic cancer.
Despite releasing positive data on its Phase III ENVISION trial, Alnylam stock dropped 7.5 percent. Although not completely clear why, the drop may be related to a high percentage of serious adverse events observed in the trial.
This morning, Boston-based Vertex said its triple-combination treatment VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two late-stage cystic fibrosis trials.
Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.
Novo Nordisk announced the results from its SUSTAIN 9 Phase IIIb trial. The trial compared Novo’s Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.
Ascendis Pharma, based in Copenhagen, Denmark, announced that its once-weekly TransCon Growth Hormone (hGH) hit its primary endpoints in its Phase III height Trial in children with pediatric growth hormone deficiency (GHD).
ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
IDMC recommends study can enrol children and infants aged from 21 days to 4 years
Shares of Maryland-based Novavax are down 66 percent in morning trading after the company announced its respiratory syncytial virus (RSV) vaccine called ResVax failed to hit its primary endpoint in a Phase III trial.
PRESS RELEASES